| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11025564 | eNeurologicalSci | 2018 | 6 Pages |
Abstract
ONO-2160 and carbidopa therapy stabilized effective plasma levodopa concentration. No adverse events with safety concerns were observed. The combination of ONO-2160 and carbidopa produced a prolonged and stable plasma levodopa concentration with a reduction in Unified Parkinson's Disease Rating Scale Part III total scores. The combination was well tolerated, with no safety concerns, when administered to Japanese patients with Parkinson's disease.
Related Topics
Life Sciences
Neuroscience
Endocrine and Autonomic Systems
Authors
Masahiro Nomoto, Masahiro Nagai, Noriko Nishikawa, Rina Ando, Yoshifumi Kagamiishi, Koji Yano, Shigeto Saito, Atsushi Takeda,